Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future (Q28289022)

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

Europe PubMed Central

title

Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future (English)

0 references

1 reference

1

Daniel H van Raalte

0 references

author name string

Min Li

series ordinal

2

0 references

P Haydn Pritchard

series ordinal

3

0 references

Kishor M Wasan

series ordinal

4

0 references

language of work or name

English

0 references

publication date

September 2004

0 references

published in

Pharmaceutical Research

0 references

volume

21

0 references

issue

9

0 references

page(s)

1531-8

0 references

cites work

1 reference

12 December 2020

The RXR heterodimers and orphan receptors

1 reference

12 December 2020

The steroid and thyroid hormone receptor superfamily

1 reference

12 December 2020

Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor

1 reference

12 December 2020

Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression

1 reference

12 December 2020

Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators

1 reference

12 December 2020

A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients

1 reference

12 December 2020

Evaluation of selected hypolipidemic agents for the induction of peroxisomal enzymes and peroxisome proliferation in the rat liver.

1 reference

12 December 2020

The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants.

1 reference

12 December 2020

PPARalpha activators inhibit tissue factor expression and activity in human monocytes

1 reference

12 December 2020

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

1 reference

12 December 2020

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

1 reference

12 December 2020

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

1 reference

12 December 2020

Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia.

1 reference

12 December 2020

Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study

1 reference

12 December 2020

Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: reduced activity of cholesterol 7 alpha-hydroxylase.

1 reference

12 December 2020

Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients

1 reference

12 December 2020

Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

1 reference

12 December 2020

The peroxisome proliferator-activated receptor alpha is a phosphoprotein: regulation by insulin

1 reference

12 December 2020

Lipid profiles on fibric-acid derivatives

1 reference

12 December 2020

Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-alpha.

1 reference

12 December 2020

Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial.

1 reference

12 December 2020

Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region

1 reference

12 December 2020

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

12 December 2020

Effects of ciprofibrate on LDL metabolism in man

1 reference

12 December 2020

Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids

1 reference

12 December 2020

Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping

1 reference

12 December 2020

Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol

1 reference

12 December 2020

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators

1 reference

12 December 2020

Mechanism of action of fibrates on lipid and lipoprotein metabolism

1 reference

12 December 2020

Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent trans-activating domain

1 reference

12 December 2020

Differential activation of peroxisome proliferator-activated receptors by eicosanoids.

1 reference

12 December 2020

Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians

1 reference

12 December 2020

cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor

1 reference

12 December 2020

Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs

1 reference

12 December 2020

How many nuclear hormone receptors are there in the human genome?

1 reference

12 December 2020

Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study

1 reference

12 December 2020

A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor

1 reference

12 December 2020

Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha.

1 reference

12 December 2020

Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects

1 reference

12 December 2020

Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study

1 reference

12 December 2020

Regulation of cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha).

1 reference

12 December 2020

Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor

1 reference

12 December 2020

Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease

1 reference

12 December 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

12 December 2020

A polymorphism, L162V, in the peroxisome proliferator-activated receptor alpha (PPARalpha) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

The PPARalpha-leukotriene B4 pathway to inflammation control.

1 reference

12 December 2020

Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate

1 reference

12 December 2020

Variation at position 162 of peroxisome proliferator-activated receptor alpha does not influence the effect of fibrates on cholesterol or triacylglycerol concentrations in hyperlipidaemic subjects

1 reference

12 December 2020

Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial

1 reference

12 December 2020

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid

1 reference

12 December 2020

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

12 December 2020

Clofibrate and niacin in coronary heart disease

1 reference

12 December 2020

Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages

1 reference

12 December 2020

Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice

1 reference

12 December 2020

Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor

1 reference

12 December 2020

Comparison of complete nuclear receptor sets from the human, Caenorhabditis elegans and Drosophila genomes

1 reference

12 December 2020

Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil

1 reference

12 December 2020

Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway

1 reference

12 December 2020

Angioscopic evaluation of stabilizing effects of an antilipemic agent, bezafibrate, on coronary plaques in patients with coronary artery disease: a multicenter prospective study

1 reference

12 December 2020

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

1 reference

12 December 2020

Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. I: Anti-atheromatous effects are independent of its hypolipidemic effect in cholesterol-fed rabbits

1 reference

12 December 2020

Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression

1 reference

12 December 2020

The murine and human cholesterol 7alpha-hydroxylase gene promoters are differentially responsive to regulation by fatty acids mediated via peroxisome proliferator-activated receptor alpha

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

Orphan nuclear receptors: from gene to function

1 reference

12 December 2020

Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate

1 reference

12 December 2020

Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects

1 reference

12 December 2020

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

1 reference

12 December 2020

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages

1 reference

12 December 2020

Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients

1 reference

12 December 2020

The pathogenesis of atherosclerosis: a perspective for the 1990s

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene

1 reference

12 December 2020

The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates

1 reference

12 December 2020

Activation of gene transcription by prostacyclin analogues is mediated by the peroxisome-proliferators-activated receptor (PPAR).

1 reference

12 December 2020

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators

1 reference

12 December 2020

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells

1 reference

12 December 2020

Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study

1 reference

12 December 2020

Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element

1 reference

12 December 2020

Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors

1 reference

12 December 2020

Molecular physiology of reverse cholesterol transport

1 reference

12 December 2020

Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells

1 reference

12 December 2020

Expression of the Peroxisome Proliferator-activated Receptor Gene Is Stimulated by Stress and Follows a Diurnal Rhythm

1 reference

12 December 2020

Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease.

1 reference

12 December 2020

Identification of a new class of steroid hormone receptors

1 reference

12 December 2020

Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

1 reference

12 December 2020

10.1023/B:PHAM.0000041444.06122.8D

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

15497675

1 reference

Consolidated OpenCitations Corpus – April 2017